Short answer
ACADIA PHARMACEUTICALS INC (ACAD) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $342M (up 22.8% year over year) with net income of $54M.
Q3 2026 key financials · XBRL
- Revenue
- $342M
- +22.8% YoY · +11.1% QoQ
- Net income
- $54M
- −25.4% YoY · +69.9% QoQ
- Operating margin
- 21.0%
- EPS (diluted)
- $0.31
- −26.2% YoY · +72.2% QoQ
Source: XBRL data from the ACADIA PHARMACEUTICALS INC (ACAD) Q3 2026 10-Q on SEC EDGAR. USD.
ACADIA PHARMACEUTICALS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $342.3M, up $63.7M YoY from $278.6M
- DAYBUE products best performer, $140.1M vs $101.1M, up $39.0M YoY
- Gross margin approximately 90% vs 92% YoY, pressured by higher DAYBUE sales mix
- Cash and investments $976.4M vs $819.7M at December 31, 2025, operating cash flow $146.3M
- Outlook: cash sufficient through and beyond next 12 months, $35.0M Neuren milestone due after first EU DAYBU sale
Risk Factors
- Newly added tariff risk triggered by U.S. pharmaceutical trade investigations, potentially raising costs and delaying supply-chain adjustments
- Most materially updated supply risk: DAYBUE API production requires approximately twelve months, increasing vulnerability to disruptions
- Regulatory risk: EU HTA Regulation entered application January 12, 2025, creating uncertain evidence requirements and reimbursement timing
- Clinical risk: RADIANT Phase 2 narrowly missed its primary endpoint, prompting removal of the 30 mg remlifanserin dosage arm
- Liquidity risk: cash, cash equivalents, investment securities and anticipated product sales expected to fund operations through and beyond the next 12 months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACADIA PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.